Paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): a narrative review and the viewpoint of the Latin American Society of Pediatric Intensive Care (SLACIP) Sepsis Committee

Jaime Fernández-Sarmiento, Daniela De Souza, Roberto Jabornisky, Gustavo Ariel Gonzalez, Maria del Pilar Arias López, Gladys Palacio

ABSTRACT

Background In this review, we discuss some important aspects of paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS), a new syndrome that is temporally related to previous exposure to SARS-CoV-2 infection. This virus has a broad spectrum of presentation that may overlap with Kawasaki disease in terms of presenting symptoms and laboratory and cardiac findings. Our objective was to review and summarise published evidence regarding the most important aspects of PIMS-TS, with special emphasis on the treatment strategies suggested for middle-income and low-income countries.

Methods A systematic review of the literature was performed in the principal medical databases including PubMed, Embase (OVID) and Google Scholar between December 2019 and August 2020.

Results A total of 69 articles were identified in the described databases. Altogether, 13 articles met the inclusion criteria and were eligible. The most frequently described symptoms of PIMS-TS include fever (82%), shock (67%) and gastrointestinal (87%), skin (71%) and cardiac disorders (75%). In most series, it has been observed between 4 and 6 weeks after the pandemic appears in the general population. Multisystem inflammatory syndrome in children is presented as a great systemic inflammatory response syndrome, which sometimes presents as shock requiring fluid resuscitation and vasoactive drug support (26%). Several treatment strategies have been used, including immunoglobulin, steroids, aspirin, anakinra and anticoagulation among others. These general and specific interventions should be guided by an interdisciplinary and multidisciplinary team, especially in settings with limited resources.

Conclusions PIMS-TS COVID-19 is a new type of presentation of SARS-CoV-2 infection, with an exaggerated inflammatory response and frequent—but not exclusive—digestive and myocardial involvement. It is important to describe the clinical course and outcomes in countries with limited resources as well as establish the role of biomarkers for early diagnosis, effective therapeutic strategies and outpatient follow-up schemes.

INTRODUCTION

In December 2019, a new viral infection was reported, causing severe respiratory infection and very high mortality. According to its genetic sequencing, this virus belongs to the genus *Beta coronavirus*, closely related to the severe acute respiratory syndrome (SARS) virus. It was named SARS-CoV-2 and its disease COVID-19.
Healthcare systems worldwide have been deeply concerned, given SARS-CoV-2’s high transmissibility, severity and lethality, particularly in the population over the age of 60 years. Patients with major comorbidities such as heart disease, diabetes, hypertension or obesity have an increased risk of dying. Moreover, mortality has been associated with multiple organ failure as the common final pathway for pneumonia, sepsis and acute respiratory distress syndrome. COVID-19 is usually less severe in paediatric patients. In general, 80%–90% of children with SARS-CoV-2 infection are asymptomatic or have a mild infection. However, between 4% and 10% of hospitalised children may need to be transferred to a paediatric intensive care unit (PICU), and mortality ranges from 0.1% to 8%. Recently, the Critical Coronavirus and Kids Epidemiology study reported a mortality rate of 5% in children hospitalised in critical care in five European and American countries (Chile, Colombia, Italy, Spain and USA), with 76% of cases having severe pneumonia as their main manifestation.

Several pathophysiological factors may explain these features. COVID-19 non-survivors have higher serum ferritin, D-dimer and C reactive protein (CRP) than those who survive, indicating an intense inflammatory response. Recently, a new type of presentation of SARS-CoV-2 infection has been described in children, involving this significant inflammatory response. This new disease has been called paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS), a new syndrome that is temporally related to previous exposure to SARS-CoV-2 infection. This is a severe presentation of the virus in children and requires early detection to avoid its progression and potentially unsatisfactory outcomes. In this article, we discuss and review the most relevant aspects of PIMS-TS described to date.

METHODS

Search strategy and article selection

A systematic review of the literature was performed in the principal medical databases including PubMed, Embase (OVID) and Google Scholar, using the Medical Subject Headings (MeSH) terms (“SARS-CoV-2” OR “Covid-19” OR “coronavirus” OR “infection” OR “sepsis” OR “Covid-19” OR “critical care”) AND “Multisystem Inflammatory Syndrome in Children” OR “MIS-C” OR “PIMS-TS” between December 2019 and August 2020. The descriptors were validated in descriptors in health science and MeSH. Grey literature or as yet unpublished documents were not included.

Eligibility criteria

Articles that reported at least five cases of PIMS-TS, including case series, case reports, and cross-sectional, case–control, cohort (either prospective or retrospective) or clinical trial studies, were included. Studies of critically ill children with COVID-19 were also considered, and the cases of PIMS-TS reported in these studies were explored. Other inclusion criteria were articles that described important outcomes such as mortality, complications, laboratory findings and treatment received. Only articles in English, Spanish or Portuguese were considered. No reports of PIMS-TS in low-income and middle-income countries were found in indexed journals. The WHO, Centers for Disease Control and Prevention (CDC) and Royal College guidelines were consulted for the definitions. Articles that did not provide complete data when reporting general cases of critically ill children with COVID-19, or those for which the full text was not available, as well as narrative reviews, were excluded. Adult cases have already been described, but these were not included in this review.

Study selection and data collection process

First, the inclusion and exclusion criteria for this systematic review were defined, after which one of the researchers (J-F-S) performed the systematic search of the literature and reviewed the most relevant articles. The established criteria were applied, and the articles were approved by all the Latin American Society of Pediatric Intensive Care (SLACIP) sepsis committee authors. In case of doubt, or a lack of consensus regarding the inclusion of an article, a second reviewer (RJ) was consulted to decide. Any discrepancies or missing data were resolved by consensus. Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed (figure 1).

Patient and public involvement statement

No patients participated actively in this review. The data were taken from the most important publications to date on PIMS-TS, including consensus recommendations for high-income countries. It is expected that this information will be disseminated through SLACIP and its various committees for applicability in patients living in middle-income and low-income countries.

RESULTS

Search and study selection results

A total of 69 articles were identified in the described databases. After eliminating the duplicates and reviews, 13 articles met the inclusion criteria and were eligible. These articles were included in the qualitative synthesis and the most relevant ones that do not include patients reported in other case series are described by their characteristics in table 1.

Although the main pathogenesis of COVID-19 may be similar to other viruses such as influenza, it has shown some clinical presentations which are different from those usually found in those classical respiratory viruses. On 24 April 2020, a new presentation of SARS-CoV-2 in children was described by Riphagen et al. in the UK. The first report described a cohort of eight children with COVID-19 who required hospitalisation in intensive care and had an unusual clinical behaviour characterised by...
a severe hyperinflammatory state, with clinical similarity between all eight patients.7–9

The Royal College of Paediatrics and Child Health called this new entity PIMS-TS.10 Subsequently, the CDC and WHO called it multisystem inflammatory syndrome in children (MIS-C).11 12 In general, both terms refer to the same entity, and the latter name has been the most frequently used in the main descriptions of this disease (box 1).

The largest series described to date is that of the CDC in Atlanta, with 570 patients. Using a latent class analysis statistical model, it attempted to divide the cases into three large groups according to their common clinical characteristics.13 Class I included those with symptoms that could overlap with macrophage activation syndrome, with a large inflammatory response. Class II had predominantly respiratory involvement and signs suggestive of active COVID-19 disease with a high rate of RT-PCR seropositivity (84%). Class III had clinical manifestations that could overlap with Kawasaki disease (KD), and only 2% were RT-PCR positive.13

In this regard, most studies report that the patients have a negative RT-PCR and positive antibody or serology tests. In fact, a negative RT-PCR has been found in 40% of patients with positive antibody tests. Although RT-PCR is an imperfect test, it is considered the gold standard today. In the described series, 46% of the cases had a positive serology and a negative RT-PCR, which suggests that, in these patients, the infection occurred possibly weeks earlier. An average of 25% of the patients in the included studies had both positive serology and positive RT-PCR (online supplemental table S1).

DISCUSSION
PIMS-TS is characterised by a very significant ongoing inflammatory response, in crescendo, which in fact has been the key element in the Atlanta CDC (14 May) and WHO (15 May) definitions (box 1).11 12 Characteristically, these patients present with high leucocytosis, CRP, procalcitonin and serum ferritin.13 Hoang et al14 reported lower expression of circulating CD16+ CD56+ natural killer cells and more profound lymphopaenia in children with PIMS-TS compared with those without PIMS-TS.

Primarily, there is an initial innate immune response with the macrophages as the principal actors. From the pathophysiological point of view, it is striking that more than 90% of children with PIMS-TS have elevated CRP and ferritin. CRP is an acute phase reactant that usually rises after 6 hours of an inflammatory state and is produced by hepatocytes and adipose tissue in response to interleukin (IL)-1, IL-6 and TNF-α (tumor necrosis factor alpha) stimulation.15 16 This acute phase reactant from the pentraxin family identifies phosphatidylserine on the surface of cells that have initiated a programmed cell death pattern of apoptosis by activating the complement system. This biomarker is very useful for diagnosis and follow-up, especially in middle-income and low-income countries (given its low cost) and should be considered on admission with subsequent follow-up.
<table>
<thead>
<tr>
<th>Author</th>
<th>City, country</th>
<th>Period</th>
<th>Number</th>
<th>Age</th>
<th>Gender</th>
<th>Comorbidity</th>
<th>Race</th>
<th>IMC kg/m²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whittaker et al</td>
<td>London, UK</td>
<td>23 March and 16 May</td>
<td>58</td>
<td>9 years (IQR 5.7–14)</td>
<td>43%</td>
<td>7/58 comorbidities</td>
<td>69% black or Asian</td>
<td>N/R</td>
</tr>
<tr>
<td>Riphagen et al</td>
<td>London, UK</td>
<td>10 days in mid-April</td>
<td>8</td>
<td>4–14 years (range)</td>
<td>5/8</td>
<td>None</td>
<td>6/8 Afro-Caribbean</td>
<td>14–33</td>
</tr>
<tr>
<td>Verdoni et al</td>
<td>Bergamo, Italy</td>
<td>18 February and 20 April</td>
<td>10</td>
<td>7.5 years (SD 3–5)</td>
<td>7/10</td>
<td>N/R</td>
<td>N/R</td>
<td>N/R</td>
</tr>
<tr>
<td>Belhadjer et al</td>
<td>France (12 hospitals) and Swiss</td>
<td>22 March–30 April</td>
<td>35</td>
<td>10 years (IQR 8.2–12.4)</td>
<td>51%</td>
<td>Comorbidities 28% (asthma 8.55; lupus 3%)</td>
<td>N/R</td>
<td>Overweight 17%</td>
</tr>
<tr>
<td>Golfred-Cato et al</td>
<td>Multicentre US</td>
<td>1 March–29 July</td>
<td>570</td>
<td>8 (IQR 4–12)</td>
<td>55.4%</td>
<td>Comorbidities 8%</td>
<td>40.5% Hispanic and 33.1% black non-hispanic</td>
<td>Obesity 25.6%</td>
</tr>
<tr>
<td>Cheung et al</td>
<td>New York, USA</td>
<td>18 April and 5 May</td>
<td>17</td>
<td>8 years (IQR 1.8–16)</td>
<td>47%</td>
<td>Most were previously healthy (mild asthma in 3)</td>
<td>White 70%</td>
<td>N/R</td>
</tr>
<tr>
<td>Kaushik et al</td>
<td>New York, USA</td>
<td>23 April–23 May</td>
<td>33</td>
<td>10 years (IQR 6–13)</td>
<td>61%</td>
<td>Comorbidities 48%</td>
<td>45% Hispanic/latino</td>
<td>Overweight 12%</td>
</tr>
<tr>
<td>Ramcharan et al</td>
<td>UK</td>
<td>10 April and 9 May</td>
<td>15</td>
<td>8.8 (IQR 6.4–11.2)</td>
<td>93%</td>
<td>over 5 years</td>
<td>100% African/Afro-Caribbean (40%), South Asian, (40%) Mixed (13%) or other minority ethnic</td>
<td>N/R</td>
</tr>
<tr>
<td>Toubiana et al</td>
<td>Paris, France</td>
<td>27 April and 11 May</td>
<td>21</td>
<td>7.9 years (IQR 3.7–16.6)</td>
<td>43%</td>
<td>N/R</td>
<td>57% sub-Saharan Africa/Caribbean islands</td>
<td>76% had a BMI below the 97th centile</td>
</tr>
<tr>
<td>Pouletty et al</td>
<td>Paris, France</td>
<td>Since April 2020</td>
<td>16</td>
<td>10 (IQR 4.7–12.5)</td>
<td>50%</td>
<td>Comorbidities 37%</td>
<td>N/R</td>
<td>Overweight 25%</td>
</tr>
<tr>
<td>Capone et al</td>
<td>New York, USA</td>
<td>17 April–13 May</td>
<td>33</td>
<td>8.6 years (IQR 5.5–12.6)</td>
<td>61%</td>
<td>Comorbidities 21%</td>
<td>73% non-Hispanic</td>
<td>Overweight 6%</td>
</tr>
<tr>
<td>Feldstein et al</td>
<td>Multicentre, USA</td>
<td>15 March–20 May</td>
<td>186</td>
<td>8.3 years (IQR 3.3–12.5)</td>
<td>62%</td>
<td>Comorbidities 27%</td>
<td>31% Hispanic, 25% black non-Hispanic</td>
<td>Obesity 29%</td>
</tr>
<tr>
<td>Dufort et al</td>
<td>New York City</td>
<td>1 March–10 May</td>
<td>95</td>
<td>0–5 years (31%) 6–12 years (42%) 13–20 years (27%)</td>
<td>54%</td>
<td>Comorbidities 64%</td>
<td>40% Black</td>
<td>Obesity 29%</td>
</tr>
</tbody>
</table>

BMI, body mass index; N/R, not reported; PIMS-TS, paediatric inflammatory multisystem syndrome temporally associated with COVID-19.
Box 1 Royal College of Paediatrics and Health Child (RCPCH), Centers for Disease Control and Prevention (CDC) and WHO definitions criteria for paediatric inflammatory multisystem syndrome temporally associated with COVID-19

RCPCH definition
1. A child presenting with persistent fever, inflammation (neutrophilia, elevated C reactive protein (CRP) and lymphopaenia) and evidence of single or multiorgan dysfunction (shock, cardiac, respiratory, renal, gastrointestinal or neurological disorder) with additional features. This may include children fulfilling full or partial criteria for Kawasaki disease.
2. Exclusion of any other microbial cause, including bacterial sepsis, staphylococcal or streptococcal shock syndromes, infections associated with mycarditis such as enterovirus (waiting for results of these investigations should not delay seeking expert advice).
3. SARS-CoV-2 PCR testing may be positive or negative.

CDC definition
1. An individual aged <21 years presenting with fever*, laboratory evidence of inflammation† and evidence of clinically severe illness requiring hospitalisation, with multisystem (>2) organ involvement (cardiac, renal, respiratory, haematological, gastrointestinal, dermatological or neurological).
2. No alternative plausible diagnoses.
3. Positive for current or recent SARS-CoV-2 infection by RT-PCR, serology or antigen test; or COVID-19 exposure within the 4 weeks prior to the onset of symptoms.

WHO definition
Children and adolescents 0–19 years of age with fever >3days. And two of the following:
1. Rash or bilateral non-purulent conjunctivitis or mucocutaneous inflammation signs (oral, hands or feet).
2. Hypotension or shock.
3. Features of myocardial dysfunction, pericarditis, valvulitis or coronary abnormalities (including ECHO findings or elevated troponin/NT-proBNP).
4. Evidence of coagulopathy (by PT, PTT and elevated D-dimers).
5. Acute gastrointestinal problems (diarrhoea, vomiting or abdominal pain).
And
Elevated markers of inflammation such as ESR, CRP or procalcitonin.
And
No other obvious microbial cause of inflammation, including bacterial sepsis, staphylococcal or streptococcal shock syndromes.
And
Evidence of COVID-19 (RT-PCR, antigen test or serology positive) or likely contact with patients with COVID-19.

*Fever >38.0°C for ≥24 hours or report of subjective fever lasting ≥24 hours. †Including, but not limited to, one or more of the following: an elevated CRP, erythrocyte sedimentation rate, fibrinogen, procalcitonin, D-dimer, ferritin, lactate dehydrogenase or interleukin 6, elevated neutrophils, reduced lymphocytes and low albumin.

Additionally, a marked elevation of ferritin (2–10 times its normal value) has been observed in more than 90% of the series. Ferritin is a protein that stores iron and releases it in a controlled fashion but also in pathophysiological conditions. Its levels can reflect macrophage response to free haemoglobin as well as DNA viruses, intracellular bacterial infections and parasites. Ferritin can induce positive feedback inflammation, upregulating toll-like receptor 9 (TLR-9), which leads macrophage inflammasome IL-1 and IL-18 to feed forward ferritin production. TLR-9 may also be stimulated by viral DNA, other infections and host damage-associated molecular patterns (DAMPs). This whole process generates a large number of inflammasomes and an enhanced inflammatory pathway, delivering the ‘cytokine storm’. This precipitate cell death with a pyroptosis pattern and new DAMPs that stimulate TLR-9. This was described as ‘Hyperferritinemic Syndrome’ by Rosário et al.

Nevertheless, there is evidence of an unusual late adaptive immune response. It has come to the researchers’ attention that PIMS-TS occurred between 4 and 6 weeks after the peak of cases reported as positive for SARS-CoV-2 in each country had been reached. Pérez-Toledo et al recently described eight patients with PIMS-TS with a negative RT-PCR but with significant elevation of IgG and IgA and negative IgM. Additionally, they found elevated IgG1 and IgG3 in these children, which are immunoglobulin isotypes associated with serum supplement activation. This situation is consistent with highly elevated CRP related to COVID-19, which activates the complement system. The elevation of these immunoglobulins suggests that PIMS-TS occurs due to tissue damage induced by autoantibodies, a situation that has been described in other types of coronavirus infection. We are not aware of any studies in middle-income and low-income countries that have described this serological behaviour. Studies are needed to help clear up this aspect, especially when all the diagnostic test options for SARS-CoV-2 are not always available. In these countries with limited resources, we suggest taking an initial RT-PCR. If this is negative and there is a high index of suspicion of PIMS-TS, due to the signs and symptoms, a total antibody or IgM/IgG test should be performed.

For PIMS-TS, most of the series described coagulation disorders. Severe coagulopathy was seen in 70%–80% of the cases (very high D-dimers, prolonged PT and PTT). Like inflammation, coagulation is necessary for host defence. In addition, proinflammatory cytokines, monocytes/macrophages, neutrophil activation and extra-cellular neutrophil traps can foster local thrombosis. COVID-19 associated coagulopathy (CAC) is complex and in some ways pathophysiologically different from SIC.

Cytokine levels of IL-1β and IL-6 are elevated, which induces thrombocytosis and hyperfibrinogenemia, and the ACE-2 receptor is stimulated by SARS-CoV-2, leading to a massive release of plasminogen activators. D-dimer levels are very high in PIMS-TS, but consumptive coagulopathy is rare in its early phase. Elevated D-dimer levels can be present in a wide variety of inflammatory and prothrombotic conditions; in COVID-19, these are probably more associated with inflammation than thrombosis. Furthermore, serum hyaluronic acid, a key
glycocalyx component, is higher during infancy, progressively diminishing over the years. This could explain a more protected endothelium and a lower probability of a hypercoagulable state. In addition, CAC has an overlapping pathophysiology with other coagulopathies like haemophagocytic syndrome/haemophagocytic lymphohistiocytosis, antiphospholipid syndrome and thrombotic thrombocytopaenic purpura/haemolytic uremic syndrome, but some unique aspects make it a probably new type of coagulopathy.

From a clinical and laboratory perspective, PIMS-TS has usually been seen in previously healthy and frequently obese (30%–60% of the series) children over 8 years of age (80% of the cases) (table 1). Initially, the group from the UK found MIS-C in patients of African descent, but it has been described in patients of all origins. Persistent high fever for more than three to five consecutive days, maculopapular skin lesions (50%–60%) reminiscent of KD and, frequently, signs of shock at the time of presentation have been the initial clinical characteristics. Digestive symptoms (including nausea, vomiting, diarrhoea or abdominal pain) usually present in most cases, as well as myocardial involvement (more than 60% of the series). Cardiac involvement is broad and variable, with features including myocardial dysfunction (100% of the initial UK description and 60% in other series), coronary aneurysms, pericarditis, arrhythmias, refractory shock and elevated troponin I or proBNP (online supplemental table S1).

Guidelines for PIMS-TS management in middle-income and low-income countries

With regard to treatment in middle-income and low-income countries, it is very important to maintain a high index of suspicion. Therefore, in these countries, it is important to use a systematic approach including early recognition and a bundle similar to those recommended for patients with other serious diseases. An expert consensus recently published in the UK using the Delphi method provides a good summary of the recommended treatments. This approach is recommended for high-income countries. Using the evidence found, we adapted these recommendations, together with those of the SCCM (Society of Critical Care Medicine) sepsis consensus, for use in middle-income and low-income countries. We believe that a comprehensive approach to PIMS-TS patients is necessary and that taking these recommendations as a whole could have an impact on the outcomes of PIMS-TS patients in these countries.

From the first presentation to the emergency department and/or PICU, two approaches can be assumed: one general and one specific (box 2):

General approach

A comprehensive approach should be used, similar to that recommended for patients with sepsis with organ dysfunction or septic shock. In this case, the contagiousness of SARS-CoV-2 requires the use of personal protective equipment that prevents the spread of the virus, particularly in patients with a positive RT-PCR.

Moreover, the American College of Critical Care Medicine points out the need to give more attention to institutional practice guidelines (IPGs) based on each facility’s capability. Once IPGs are established, diagnostic and therapeutic measures known as ‘patient care bundles’ (PCBs) should be developed for a better approach and control of established processes. The PCBs include three to five evidence-based practices related to a healthcare process that should be performed collectively to achieve a synergistic result that improves care.

1. Early detection: a comprehensive approach based on a high index of suspicion is critical. This disease may occur with a wide spectrum of symptoms, so it should be suspected in all patients with a fever lasting more than 3 days associated with the symptoms described in box 1. Contact with a positive case is not always clear.

2. Immediate, time-sensitive resuscitation:
   - Oxygen therapy: this is part of the strategies described in recent sepsis guidelines. High flow nasal cannulas and non-invasive ventilation have been considered in many reports, especially in patients who have a deteriorated respiratory pattern with the use of accessory muscles or an SaO2/FiO2 ratio less than 264. Most series describe respiratory involvement ranging from 20% to 60% (online sup-

---

**Box 2** Summary of recommendations for management of paediatric inflammatory multisystem syndrome temporally associated with COVID-19 in countries with limited resources

### A. General approach

1. Early detection.
2. Immediate, time-sensitive resuscitation
   - Oxygen therapy.
   - Fluid resuscitation.
   - Vasoactive drugs.
   - Antibiotic therapy: if bacterial coinfection is suspected.
3. Stabilisation with adequate monitoring.
4. Timely referral or transfer according to the context and available resources.
5. Continuous measurement of processes.

### B. Specific approach

1. Human immunoglobulin: 2 g/kg for moderate to severe cases.
2. Steroids:
   - 1–2 mg/kg/dose of methylprednisolone three or four times per day.
   - High doses in cases of shock with high vasopressor requirement.
3. Anakinra:
   - Only in cases refractory to steroids and IVIG (intravenous immune globulin). Not available in all countries.
4. Anticoagulation is recommended for:
   - Documented thrombosis.
   - Echocardiogram with an EF(ejection fraction) of less than 35%.
5. Antithrombotic treatment: recommended for thrombocytosis >450,000 µ/L.

---
plemental table S1) and, generally, if endotracheal intubation is required, it is more highly associated with cardiovascular involvement. Cases classified as class II by the CDC may be classified in these groups.33 38

- Fluid resuscitation: it is important to consider the recommendations in recently published guidelines.16 In healthcare systems where staff and equipment for advanced airway management are available, up to 40–60mL/kg (10–20mL/kg per bolus) of balanced crystalloids (Ringer’s lactate or Plasma-Lyte) can be given over the first hour, titrated to clinical markers of cardiac output and discontinued if signs of fluid overload develop. In healthcare systems without the availability of intubation, crystalloid boluses may only be given in cases of hypotension (decompensated shock); in these cases, up to 40mL/kg of bolus fluid (10–20mL/kg per bolus) may be infused over the first hour with titration to clinical markers of cardiac output, and discontinued if signs of fluid overload develop. If the child is not hypotensive, but has compensated shock, only maintenance fluids should be started, avoiding bolus fluids that are associated with worse outcomes.35–38

- Vasoactive drugs: according to the clinical condition, most series describe the need for vasoactive drugs in 10%–60% of the cases with PIMS-TS. Most patients respond to fluid resuscitation. If necessary, epinephrine or norepinephrine should be considered according to the patient’s condition.16 39 Inotropes like dopamine, milrinone and levosimendan were reported to have been used in PIMS-TS.38–40

- Antibiotic therapy: if bacterial coinfection is suspected, the first dose is recommended within the first 3 hours for sepsis associated with organ dysfunction or within the first hour for children with septic shock.39–41

3. Stabilisation with adequate monitoring: if possible, advanced haemodynamic monitoring should be instituted. Cardiac ultrasound/echocardiography or Swave measurements have been suggested by recent guidelines16 and patients with PIMS-TS.42

4. Timely referral or transfer is desirable in this context. In middle-income and low-income countries, it is common for patients to be transferred to higher complexity sites. Patients who are deteriorating or who may need intensive care should be identified. In the PIMS-TS of the CDC group, 84% of the cases had to be transferred to paediatric intensive care.16 40–42

5. Continuous measurement of processes and corrections must be instituted for a continuous quality improvement process.43

Specific approach

It is important to emphasise that, in moderate to severe cases, the use of immunomodulatory treatment should be considered. Heterogeneous management including human immunoglobulin, systemic steroids, anakinra, tocilizumab and aspirin40 42–45 has been reported in the described series (online supplemental table S1). The American College of Rheumatology (ACR) recommendations for immunomodulatory therapy42 have recently been published. We sought to adapt these recommendations to middle-income and low-income countries where resources are limited and each intervention must be streamlined according to need.

- IVIG: high doses (2g/kg) should be considered for moderate to severe cases, particularly those with myocardial involvement. Prior to beginning the infusion, restored heart function must be verified.42

- Steroids: steroids have recently been shown to be useful in modifying the clinical course of the disease in adults with severe pneumonia, particularly if they are on mechanical ventilation.43–47 In patients with PIMS-TS, low doses could be considered in all cases (used in 70% of the series; online supplemental table S1). Dosing schemes of 1–2mg/kg/dose of methylprednisolone or its equivalent three or four times per day have been recommended. The ACR suggests considering high doses in cases of shock or in those with a high need for vasopressors, and we believe this recommendation is very important for middle-income and low-income countries, especially considering the frequency of late consults with advanced disease.

- Anakinra is suggested by the ACR consensus for use in cases of steroid or IVIG-refractory PIMS-TS.42 However, in many countries, its use is not approved, or it is not available, and other biological agents are used. Prospective studies are needed to evaluate the efficacy and safety of these medications in PIMS-TS.

- Anticoagulation and antiplatelet treatment: anticoagulation has become a fundamental treatment in adults, considering that there is a procoagulant and hypofibrinolytic state in severe SARS-CoV-2 infection.42 47–50 In children with PIMS-TS, it is recommended only in cases of documented thrombosis or in patients with an echocardiogram ejection fraction less than 35%.43 47 Aspirin would also be recommended in patients with thrombocytosis (>450000µ/L) or Kawasaki-like disease criteria.42 47

The prognosis of the disease is usually good, with patient survival greater than 95% in different published series.36 42–50 A mortality of 1%–2% has been described in the published series and up to 15% with cardiovascular sequelae, including aneurysms or dysfunction.35 48–50

These patients should be followed up after discharge by interdisciplinary and multidisciplinary teams including infectious disease, rheumatology and paediatrics. However, there are incomplete data from all the cases, along with a knowledge gap regarding mild and moderate cases, the natural course and the clinical behaviour of the disease.47–50
CONCLUSION

PIMS-TS is a new type of presentation of SARS-CoV-2 infection, with an exaggerated inflammatory response and inadequate inflammatory resolution with frequent—but not exclusive—digestive and myocardial involvement. It should be considered as a new disease with unique symptoms, a greater variety of clinical courses and possibly different physiological mechanisms. In middle-income and low-income countries, studies should be performed to learn more about this disease in these regions and determine if they have different phenotypic behaviours. In addition, the real role of some inflammatory biomarkers and cost-effective therapeutic strategies should be determined.

REFERENCES


<table>
<thead>
<tr>
<th>Author</th>
<th>Clinical presentation</th>
<th>ECHO</th>
<th>SARS-CoV-2 test</th>
<th>Organ support</th>
<th>Treatment</th>
<th>Outcome / Died</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whittaker et al [3]</td>
<td>Fever 100%, Headache 26% Vomiting 45% Abdominal pain 53%, Rash 52% Conjunctivitis 45% Lymphadenopathy 16% Mucus membrane, changes/red cracked lips 29% Swollen hands and feet 16%, Respiratory symptoms 21%. Fever + elevated inflammatory markers – 40%, Shock - 50%</td>
<td>Left ventricular dysfunction 62% (18/29) Abnormally dilated coronary arteries (z score &gt; 2) 8/55 Giant coronary artery aneurysms 2 Coronary artery aneurysm 14% (n=8)</td>
<td>RT-PCR SARS-CoV-2 + 26% IgG antibody SARS-CoV-2 + 87% 78% had evidence of current or prior SARS-CoV-2 infection</td>
<td>PICU 50% Acute kidney injury 22% Shock + inotropic support 47% MV 43% ECMO 5%</td>
<td>Inotropic support 47% IVIG 71% Corticosteroids 64% Anakinra 5% Infliximab 14%</td>
<td>Death 2%</td>
</tr>
<tr>
<td>Verdoni et al [7]</td>
<td>Classic form of Kawasaki 50%, Incomplete form of Kawasaki disease 50% KDss and MAS 50% Diarrhoea 60% Meningeal signs 40% Drowsiness 10%</td>
<td>Anormal ECHO 60% Aneurism 10% FEVE &lt; 50% – 50% Mitral valve regurgitation 10% Pericardial effusion 40%</td>
<td>RT-PCR SARS-CoV-2 + 20% Serology for SARS-CoV-2 antibodies – 80% were IgG +, and 3 were also IgM +</td>
<td></td>
<td>Inotropic support 20% Adjunctive steroid treatment 80% IVIG 100% Aspirin 20%</td>
<td>None</td>
</tr>
<tr>
<td>Belhadjer et al [8]</td>
<td>Asthenia 100% Fever 100% GI symptoms 83% (2 children underwent emergency operation for suspected appendicitis) Respiratory distress 65%</td>
<td>Coronary artery dilatation (z score &gt; 2) 17% Aneurysm 0 LVEF &lt; 30% - 28% LVEF 30-50% - 72%</td>
<td>SARS-CoV-2 was confirmed 88.5% RT-PCR-SARS-CoV-2 + 34% Fecal PCR 6% Antibodies + 86%</td>
<td>Respiratory support 94% (IMV 62%, NIV 32%)</td>
<td>Inotropic support 80% IVIG 71% Corticosteroids 34% Anakinra 8% Anticoagulation with heparin 65%</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>Rhinorrhea 43%</td>
<td>Adenopathy 60%</td>
<td>Rash 57%</td>
<td>Meningism 31%</td>
<td>At admission to the ICU, 80% were in cardiogenic shock</td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td>Grimaud et al [9]</td>
<td>Fever 100%, Abdominal pain 100%, Rash 50%, Conjunctivitis 30%, Adenitis 20%, Tachycardia 100%, Hypotension 100% (75% clinical signs of vasoplegia)</td>
<td>LVEF 35% (IQR 25-55)</td>
<td>SARS-CoV-2 nasopharyngeal swabs + 50% SARS-CoV-2 antibodies + 100% (15/15), 95% had identified SARS-CoV-2 infection on PCR and/or by serology</td>
<td>NIV 55%, IMV 40%, HFNO 5%, Respiratory support in all patient was indicated for hemodynamic support</td>
<td>IVIG 100%. Corticosteroids 10%, Anakinra 5%, Tocilizumab 5%, Inotropic/vasopressor support 95%</td>
<td></td>
</tr>
<tr>
<td>Cheung et al [33]</td>
<td>Fever 100% GI symptoms 88% Shock at presentation 76% Rash 71%, Conjunctivitis 65% Lip redness/swelling 65% Neurologic symptoms 47%, Respiratory symptoms 41%, Myalgia 35%, Lymphadenopathy 35%, Hypoxia 18% Criteria for KD 47% Incomplete Kawasaki 29%</td>
<td>FEVE mildly decreased 29%</td>
<td>RT-PCR SARS-CoV-2 + 47% Serology for SARS-CoV-2 antibodies + 53%</td>
<td>PICU 88%</td>
<td>IVIG 76%. Methylprednisolone 71% Hydrocortisone 21% Enoxaparin prophylaxis 59% Enoxaparin treatment 6% Aspirin 24%</td>
<td></td>
</tr>
<tr>
<td>Golfred-Cato S et al [13]</td>
<td>Fever 100% Bilateral conjunctival injection 48.4% Oral mucose changes 23% Rash 55.3%</td>
<td>Abnormal ECHO with coronary-artery aneurysms 18.6%</td>
<td>RT-PCR 25.8% Serology positive 46.1% RT-PCR and serology positive 27.2%</td>
<td>PICU 63.9% MV 13.1% Vasoactives 44.9%</td>
<td>IVIG 80.5%. Steroids 62.8% Antiplatelet medication 58.6% Anticoagulation 44.2% Died 1.8% Organs sistems involved 4-5 61.6%</td>
<td></td>
</tr>
<tr>
<td>Kaushik et al [38]</td>
<td>Fever 93%, Abdominal pain 63%, Nausea/emesis 69%, Diarrhea 48%</td>
<td>Pericardial effusion 46%</td>
<td>SARS-CoV-2 antibody + 81%</td>
<td>NIV 36% IMV 15% ECMO 3%</td>
<td>IVIG 54%. Corticosteroids 51%, Tocilizumab 36% Death 3%</td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Hypotension</td>
<td>Mucocutaneous involvement</td>
<td>Conjunctivitis</td>
<td>Rash</td>
<td>Shortness of breath</td>
<td>Neurologic involvement</td>
</tr>
<tr>
<td>-------</td>
<td>-------------</td>
<td>--------------------------</td>
<td>---------------</td>
<td>------</td>
<td>---------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>Ramcharan et al [40]</td>
<td>Hypotension 63%, Mucocutaneous involvement 21%, Conjunctivitis 36%, Rash 42%, Shortness of breath 33%, Neurologic involvement 12%</td>
<td>LVEF median 46.6 (IQR 39.5, 52.8)</td>
<td>LVEF &lt; 30%: 12%, LVEF 30-50%: 53%, Recovered LV function prior to discharge 95%</td>
<td>RT-PCR SARS-CoV-2 + 33%, 18% tested + for both</td>
<td>Intra-aortic balloon pump support 3%</td>
<td>Remdesivir 21%, Anakinra 12%, Convalescent plasma therapy 3%, Aspirin 24%, Anticoagulation, prophylaxis 15%, Anticoagulation, therapeutic 81%</td>
</tr>
<tr>
<td>Toubiana et al [45]</td>
<td>Recent history of viral-like symptoms was report in 43% Median duration between these symptoms and the onset of signs and symptoms of Kawasaki disease was 45 days. Complete presentation of KD 52%, Abdominal symptoms 95%, Lips and oral cavity changes 76%, Conjunctivitis 81%, Rash 76%, Changes to extremities 48%, Lymphadenopathy 57%</td>
<td>Myocarditis 76% (LVFE range between 10 and 57%)</td>
<td>38% coronary artery abnormalities: 24% which consisted of dilations (z score between 2.0 and 2.5); 14% with increased coronary visibility</td>
<td>No coronary aneurysms were identified</td>
<td>History of recent contact with people with viral-like symptoms was + in 48% Median interval between reported contact and KD was 36 days</td>
<td>RT-PCR SARS-CoV-2 + 38% IgG antibodies SARS-CoV-2 + 90% 9.5% negative Serology and PCR</td>
</tr>
</tbody>
</table>
| Pouletty et al [46] | Fever 100% Respiratory signs 12% GI signs 81% Anosmia 6% | Abnormal ECHO 69% Coronary dilatation 19% (median z score 2.6) | Family c/s COVID-19 infection 75% First infectious exposure | IVIG 93% (Second infusion 33.5) Steroids 25% | Anakinra 6% | None | BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance on this supplemental material which has been supplied by the author(s) | BMJ Paediatrics Open doi: 10.1136/bmjpo-2020-000894: e000894. 5 2021; BMJ Paediatrics Open, et al. Fernández-Sarmiento J et al. BMJ Paediatrics Open
| Caponi et al [47] | Fever 100% | GI symptoms 97% | Neurocognitive symptoms 58% | Respiratory symptoms 52% | Shock 75% | Complete KD 64% | HD without shock 76% | Any coronary abnormality 48% (Z score >= 2.5 - 15%; Z score 2.2-4.9 – 9%) | IgG + and Nucleic acid amplification + 18% | IgG + and Nucleic acid amplification negative 73% | Nucleic acid amplification +, serology test unavailable 9% | PICU 79% | MV 18% | Inotrope/vasopressor support 76% | IVIG 100% | 2nd dose IVIG 33% | Methylprednisolone 70% | Aspirin 88% | Tocilizumab 9% | Infliximab 13% | Enoxaparin 42% | None |
|------------------|------------|-----------------|-----------------------------|-------------------------|-----------|-----------------|---------------------|-----------------------------------------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------|-----------|-------------------------------|-----------------|---------------------|-------------------|-----------------|----------------|--------------------------|-----------------|
| Feldstein L.R et al [48] | Fever 100% | Bilateral conjunctival injection 55% | Oral mucose changes 42% | Peripheral extremity changes 37% | Rash 59% | Abnormal ECHO with coronary-artery aneurysms 9% | RT-PCR or antibody testing 70% | PICU 80% | MV 20% | Inotrope or vasopressor support 48% ECMO 4% | IVIG 77% | Secon dose 21% Systemic glucocorticoid 49% | Interleukin-6 inhibitor 8% | Interleukin-1Ra inhibitor 13% | Anticoagulation 47% | 28% were still hospitalized as of May 20, 2020, and 4 patients (2%) died, 2 of whom had previously been healthy. |
| Dufort E et al (49) | Fever 100%, abdominal pain 61%, rash 60%, conjunctivitis 56% | Abnormal ECHO with coronary-artery aneurysm 9% | RT-PCR 51%, IgG antibodies 99% | PICU 80%, MV 10%, Vasopressor support 62%, ECMO 4% | IVIG 48% | Systemic glucocorticoids 64% | Death 2%, shock 10%, myocarditis 53% |

Supplementary File. Table S1. Clinical findings, echocardiographic and treatments instituted in the described series of PIMS-TS